Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 320

1.

Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients.

de Goeje PL, Poncin M, Bezemer K, Kaijen-Lambers MEH, Groen HJM, Smit EF, Dingemans AC, Kunert A, Hendriks RW, Aerts JGJV.

Clin Cancer Res. 2019 Jan 14. doi: 10.1158/1078-0432.CCR-18-2243. [Epub ahead of print]

PMID:
30642911
2.

Surgical experience and patient-related restrictions predict the adequacy of cervical mediastinoscopy in non-small cell lung carcinoma lymph node staging.

Klinkenberg TJ, Bouma W, Van De Wauwer C, Wolf RFE, Mariani MA, Groen HJM.

J Cardiothorac Surg. 2018 Dec 29;13(1):134. doi: 10.1186/s13019-018-0821-7.

3.

Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study.

Walter JE, Heuvelmans MA, Ten Haaf K, Vliegenthart R, van der Aalst CM, Yousaf-Khan U, van Ooijen PMA, Nackaerts K, Groen HJM, De Bock GH, de Koning HJ, Oudkerk M.

Thorax. 2018 Dec 27. pii: thoraxjnl-2018-212152. doi: 10.1136/thoraxjnl-2018-212152. [Epub ahead of print]

PMID:
30591535
4.

Screening for Early Lung Cancer, Chronic Obstructive Pulmonary Disease, and Cardiovascular Disease (the Big-3) Using Low-dose Chest Computed Tomography: Current Evidence and Technical Considerations.

Heuvelmans MA, Vonder M, Rook M, Groen HJM, De Bock GH, Xie X, Ijzerman MJ, Vliegenthart R, Oudkerk M.

J Thorac Imaging. 2018 Dec 13. doi: 10.1097/RTI.0000000000000379. [Epub ahead of print]

PMID:
30550403
5.

Single tube liquid biopsy for advanced non-small cell lung cancer.

de Wit S, Rossi E, Weber S, Tamminga M, Manicone M, Swennenhuis JF, Groothuis-Oudshoorn CGM, Vidotto R, Facchinetti A, Zeune LL, Schuuring E, Zamarchi R, Hiltermann TJN, Speicher MR, Heitzer E, Terstappen LWMM, Groen HJM.

Int J Cancer. 2018 Dec 11. doi: 10.1002/ijc.32056. [Epub ahead of print]

PMID:
30536653
6.

Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer.

Cramer-van der Welle CM, Peters BJM, Schramel FMNH, Klungel OH, Groen HJM, van de Garde EMW; Santeon NSCLC Study Group; Santeon NSCLC study group.

Eur Respir J. 2018 Dec 20;52(6). pii: 1801100. doi: 10.1183/13993003.01100-2018. Print 2018 Dec.

7.

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.

Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schröder CP, Hiltermann TJN, van der Wekken AJ, Groen HJM, Kwee TC, Elias SG, Gietema JA, Bohorquez SS, de Crespigny A, Williams SP, Mancao C, Brouwers AH, Fine BM, de Vries EGE.

Nat Med. 2018 Dec;24(12):1852-1858. doi: 10.1038/s41591-018-0255-8. Epub 2018 Nov 26.

PMID:
30478423
8.

KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC.

Niemantsverdriet M, Schuuring E, Elst AT, van der Wekken AJ, van Kempen LC, van den Berg A, Groen HJM.

J Thorac Oncol. 2018 Dec;13(12):e249-e251. doi: 10.1016/j.jtho.2018.07.103. No abstract available.

PMID:
30467046
9.

Assessing Lung Cancer Screening Programs under Uncertainty in a Heterogeneous Population.

Broekhuizen H, Groothuis-Oudshoorn CGM, Vliegenthart R, Groen HJM, IJzerman MJ.

Value Health. 2018 Nov;21(11):1269-1277. doi: 10.1016/j.jval.2018.01.021.

PMID:
30442273
10.

Relationship between the number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: The NELSON study.

Walter JE, Heuvelmans MA, de Bock GH, Yousaf-Khan U, Groen HJM, van der Aalst CM, Nackaerts K, van Ooijen PMA, de Koning HJ, Vliegenthart R, Oudkerk M.

Lung Cancer. 2018 Nov;125:103-108. doi: 10.1016/j.lungcan.2018.05.007. Epub 2018 May 14.

11.

Reply to A. Addeo et al, H. Zeng et al, and C.G. Rusthoven.

De Ruysscher DK, Groen HJ.

J Clin Oncol. 2018 Oct 22:JCO1800863. doi: 10.1200/JCO.18.00863. [Epub ahead of print] No abstract available.

PMID:
30346900
12.

A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors.

Atrafi F, Groen HJM, Byers LA, Garralda E, Lolkema MP, Sangha RS, Viteri S, Chae YK, Camidge DR, Gabrail NY, Hu B, Tian T, Nuthalapati S, Hoening E, He L, Komarnitsky P, Calles A.

Clin Cancer Res. 2019 Jan 15;25(2):496-505. doi: 10.1158/1078-0432.CCR-18-2014. Epub 2018 Oct 16.

PMID:
30327308
13.

Classification of Cells in CTC-Enriched Samples by Advanced Image Analysis.

de Wit S, Zeune LL, Hiltermann TJN, Groen HJM, Dalum GV, Terstappen LWMM.

Cancers (Basel). 2018 Oct 10;10(10). pii: E377. doi: 10.3390/cancers10100377.

14.

Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition.

de Boer HR, Pool M, Joosten E, Everts M, Samplonius DF, Helfrich W, Groen HJM, van Cooten S, Fusetti F, Fehrmann RSN, de Vries EGE, van Vugt MATM.

Oncogene. 2019 Feb;38(9):1477-1488. doi: 10.1038/s41388-018-0522-7. Epub 2018 Oct 10.

PMID:
30305724
15.

Respiratory level tracking with visual biofeedback for consistent breath-hold level with potential application in image-guided interventions.

Heerink WJ, Dorrius MD, Groen HJM, Van Ooijen PMA, Vliegenthart R, Oudkerk M.

Eur Radiol Exp. 2018 Sep 5;2:22. doi: 10.1186/s41747-018-0052-7. eCollection 2018 Dec.

16.

Prophylactic cranial irradiation (PCI) in locally advanced non-small cell lung cancer: time for hope?

De Ruysscher DK, Groen HJ.

Oncotarget. 2018 Aug 17;9(64):32274-32275. doi: 10.18632/oncotarget.25866. eCollection 2018 Aug 17. No abstract available.

17.

[An enlarged thymus associated with Graves' disease].

Wouters MPAM, Wolffenbuttel BHR, Links TP, Groen HJM, Wouters RSME.

Ned Tijdschr Geneeskd. 2018 Jul 20;162. pii: D2905. Dutch.

PMID:
30182634
18.

Developing Ultrasensitive Library-Aliquot-Based Droplet Digital PCR for Detecting T790M in Plasma-Circulating Tumor DNA of Non-small-Cell-Lung-Cancer Patients.

Yang K, Li J, Zhao J, Ren P, Wang Z, Wei B, Dong B, Sun R, Wang X, Groen HJM, Ma J, Guo Y.

Anal Chem. 2018 Oct 2;90(19):11203-11209. doi: 10.1021/acs.analchem.8b01776. Epub 2018 Sep 11.

PMID:
30156405
19.

Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?

van der Wekken AJ, Kok K, Groen HJM.

J Thorac Dis. 2018 Jul;10(Suppl 18):S2130-S2132. doi: 10.21037/jtd.2018.06.45. No abstract available.

20.

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification.

Meedendorp AD, Ter Elst A, 't Hart NA, Groen HJM, Schuuring E, van der Wekken AJ.

Front Oncol. 2018 May 22;8:176. doi: 10.3389/fonc.2018.00176. eCollection 2018.

21.

Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study.

De Ruysscher D, Dingemans AC, Praag J, Belderbos J, Tissing-Tan C, Herder J, Haitjema T, Ubbels F, Lagerwaard F, El Sharouni SY, Stigt JA, Smit E, van Tinteren H, van der Noort V, Groen HJM.

J Clin Oncol. 2018 Aug 10;36(23):2366-2377. doi: 10.1200/JCO.2017.77.5817. Epub 2018 May 22.

PMID:
29787357
22.

New Subsolid Pulmonary Nodules in Lung Cancer Screening: The NELSON Trial.

Walter JE, Heuvelmans MA, Yousaf-Khan U, Dorrius MD, Thunnissen E, Schermann A, Groen HJM, van der Aalst CM, Nackaerts K, Vliegenthart R, de Koning HJ, Oudkerk M.

J Thorac Oncol. 2018 Sep;13(9):1410-1414. doi: 10.1016/j.jtho.2018.05.006. Epub 2018 Jul 12.

PMID:
29775805
23.

Characteristics of new solid nodules detected in incidence screening rounds of low-dose CT lung cancer screening: the NELSON study.

Walter JE, Heuvelmans MA, Bock GH, Yousaf-Khan U, Groen HJM, Aalst CMV, Nackaerts K, Ooijen PMAV, Koning HJ, Vliegenthart R, Oudkerk M.

Thorax. 2018 Aug;73(8):741-747. doi: 10.1136/thoraxjnl-2017-211376. Epub 2018 Apr 16.

PMID:
29661918
24.

Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.

Li J, Wang Z, Groen HJM, Zhao J, Wang P, Zhang C, Yang K, Guo Y, Ma J.

Lung Cancer. 2018 Apr;118:173-175. doi: 10.1016/j.lungcan.2018.02.016. Epub 2018 Mar 2. No abstract available.

PMID:
29502892
25.

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers.

Wei J, van der Wekken AJ, Saber A, Terpstra MM, Schuuring E, Timens W, Hiltermann TJN, Groen HJM, van den Berg A, Kok K.

Cancers (Basel). 2018 Jan 4;10(1). pii: E10. doi: 10.3390/cancers10010010.

26.

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

Felip E, Barlesi F, Besse B, Chu Q, Gandhi L, Kim SW, Carcereny E, Sequist LV, Brunsvig P, Chouaid C, Smit EF, Groen HJM, Kim DW, Park K, Avsar E, Szpakowski S, Akimov M, Garon EB.

J Thorac Oncol. 2018 Apr;13(4):576-584. doi: 10.1016/j.jtho.2017.11.131. Epub 2017 Dec 13.

PMID:
29247830
27.

Resource utilization in lung cancer diagnostic procedures: Current use and budget consequences.

Brinkhof S, Groen HJM, Siesling SS, IJzerman MJ.

PLoS One. 2017 Dec 7;12(12):e0189251. doi: 10.1371/journal.pone.0189251. eCollection 2017.

28.

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.

Horn L, Gettinger S, Camidge DR, Smit EF, Janjigian YY, Miller VA, Pao W, Freiwald M, Fan J, Wang B, Chand VK, Groen HJM.

Lung Cancer. 2017 Nov;113:51-58. doi: 10.1016/j.lungcan.2017.08.014. Epub 2017 Aug 31.

29.

Relationship between nodule count and lung cancer probability in baseline CT lung cancer screening: The NELSON study.

Heuvelmans MA, Walter JE, Peters RB, Bock GH, Yousaf-Khan U, Aalst CMV, Groen HJM, Nackaerts K, Ooijen PMV, Koning HJ, Oudkerk M, Vliegenthart R.

Lung Cancer. 2017 Nov;113:45-50. doi: 10.1016/j.lungcan.2017.08.023. Epub 2017 Sep 1.

30.

Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.

Derks JL, Leblay N, Thunnissen E, van Suylen RJ, den Bakker M, Groen HJM, Smit EF, Damhuis R, van den Broek EC, Charbrier A, Foll M, McKay JD, Fernandez-Cuesta L, Speel EM, Dingemans AC; PALGA-Group.

Clin Cancer Res. 2018 Jan 1;24(1):33-42. doi: 10.1158/1078-0432.CCR-17-1921. Epub 2017 Oct 24.

31.

Molecular Tumor Boards: current practice and future needs.

van der Velden DL, van Herpen CML, van Laarhoven HWM, Smit EF, Groen HJM, Willems SM, Nederlof PM, Langenberg MHG, Cuppen E, Sleijfer S, Steeghs N, Voest EE.

Ann Oncol. 2017 Dec 1;28(12):3070-3075. doi: 10.1093/annonc/mdx528.

PMID:
29045504
32.

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.

Soria JC, Adjei AA, Bahleda R, Besse B, Ferte C, Planchard D, Zhou J, Ware J, Morrissey K, Shankar G, Lin W, Schutzman JL, Dy GK, Groen HJM.

Eur J Cancer. 2017 Nov;86:186-196. doi: 10.1016/j.ejca.2017.08.027. Epub 2017 Oct 6.

PMID:
28992562
33.

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE.

Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.

PMID:
28919011
34.

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.

van der Wekken AJ, Kuiper JL, Saber A, Terpstra MM, Wei J, Hiltermann TJN, Thunnissen E, Heideman DAM, Timens W, Schuuring E, Kok K, Smit EF, van den Berg A, Groen HJM.

PLoS One. 2017 Aug 30;12(8):e0182885. doi: 10.1371/journal.pone.0182885. eCollection 2017.

35.

Quality assessment of positron emission tomography scans: recommendations for future multicentre trials.

de Jong EEC, van Elmpt W, Hoekstra OS, Groen HJM, Smit EF, Boellaard R, Lambin P, Dingemans AC.

Acta Oncol. 2017 Nov;56(11):1459-1464. doi: 10.1080/0284186X.2017.1346824. Epub 2017 Aug 22.

PMID:
28830270
36.

Transient thyrotoxicosis during nivolumab treatment.

van Kooten MJ, van den Berg G, Glaudemans AWJM, Hiltermann TJN, Groen HJM, Rutgers A, Links TP.

Neth J Med. 2017 Jun;75(5):204-207.

37.

Quantification of growth patterns of screen-detected lung cancers: The NELSON study.

Heuvelmans MA, Vliegenthart R, de Koning HJ, Groen HJM, van Putten MJAM, Yousaf-Khan U, Weenink C, Nackaerts K, de Jong PA, Oudkerk M.

Lung Cancer. 2017 Jun;108:48-54. doi: 10.1016/j.lungcan.2017.02.021. Epub 2017 Mar 1.

38.

Scientific Advances in Thoracic Oncology 2016.

Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR.

J Thorac Oncol. 2017 Aug;12(8):1183-1209. doi: 10.1016/j.jtho.2017.05.019. Epub 2017 Jun 1. Review.

39.

Long-term Outcome of Surgery or Stereotactic Radiotherapy for Lung Oligometastases.

Lodeweges JE, Klinkenberg TJ, Ubbels JF, Groen HJM, Langendijk JA, Widder J.

J Thorac Oncol. 2017 Sep;12(9):1442-1445. doi: 10.1016/j.jtho.2017.05.015. Epub 2017 May 30.

40.

Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?

Derks JL, van Suylen RJ, Thunnissen E, den Bakker MA, Groen HJ, Smit EF, Damhuis RA, van den Broek EC, Speel EM, Dingemans AC; PALGA group.

Eur Respir J. 2017 Jun 1;49(6). pii: 1601838. doi: 10.1183/13993003.01838-2016. Print 2017 Jun.

41.

[New biopsy at lung cancer progression: rational treatment of resistant lung cancer].

Hijmering-Kappelle LBM, van der Wekken AJ, Hiltermann TJN, Groen HJM.

Ned Tijdschr Geneeskd. 2017;161:D1229. Review. Dutch.

PMID:
28558851
42.

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares Rodríguez LG, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR.

J Clin Oncol. 2017 Aug 1;35(22):2490-2498. doi: 10.1200/JCO.2016.71.5904. Epub 2017 May 5.

PMID:
28475456
43.

Copy number alterations assessed at the single-cell level revealed mono- and polyclonal seeding patterns of distant metastasis in a small-cell lung cancer patient.

Ferronika P, van den Bos H, Taudt A, Spierings DCJ, Saber A, Hiltermann TJN, Kok K, Porubsky D, van der Wekken AJ, Timens W, Foijer F, Colomé-Tatché M, Groen HJM, Lansdorp PM, van den Berg A.

Ann Oncol. 2017 Jul 1;28(7):1668-1670. doi: 10.1093/annonc/mdx182. No abstract available.

PMID:
28419234
44.

CT-guided percutaneous hookwire localization increases the efficacy and safety of VATS for pulmonary nodules.

Klinkenberg TJ, Dinjens L, Wolf RFE, van der Wekken AJ, van de Wauwer C, de Bock GH, Timens W, Mariani MA, Groen HJM.

J Surg Oncol. 2017 Jun;115(7):898-904. doi: 10.1002/jso.24589. Epub 2017 Feb 23.

PMID:
28230245
45.

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer.

van der Wekken AJ, Pelgrim R, 't Hart N, Werner N, Mastik MF, Hendriks L, van der Heijden EHFM, Looijen-Salamon M, de Langen AJ, Staal-van den Brekel J, Riemersma S, van den Borne BE, Speel EJM, Dingemans AC, Hiltermann TJN, van den Berg A, Timens W, Schuuring E, Groen HJM.

Clin Cancer Res. 2017 Aug 1;23(15):4251-4258. doi: 10.1158/1078-0432.CCR-16-1631. Epub 2017 Feb 9.

46.

Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis.

Hobbs BD, de Jong K, Lamontagne M, Bossé Y, Shrine N, Artigas MS, Wain LV, Hall IP, Jackson VE, Wyss AB, London SJ, North KE, Franceschini N, Strachan DP, Beaty TH, Hokanson JE, Crapo JD, Castaldi PJ, Chase RP, Bartz TM, Heckbert SR, Psaty BM, Gharib SA, Zanen P, Lammers JW, Oudkerk M, Groen HJ, Locantore N, Tal-Singer R, Rennard SI, Vestbo J, Timens W, Paré PD, Latourelle JC, Dupuis J, O'Connor GT, Wilk JB, Kim WJ, Lee MK, Oh YM, Vonk JM, de Koning HJ, Leng S, Belinsky SA, Tesfaigzi Y, Manichaikul A, Wang XQ, Rich SS, Barr RG, Sparrow D, Litonjua AA, Bakke P, Gulsvik A, Lahousse L, Brusselle GG, Stricker BH, Uitterlinden AG, Ampleford EJ, Bleecker ER, Woodruff PG, Meyers DA, Qiao D, Lomas DA, Yim JJ, Kim DK, Hawrylkiewicz I, Sliwinski P, Hardin M, Fingerlin TE, Schwartz DA, Postma DS, MacNee W, Tobin MD, Silverman EK, Boezen HM, Cho MH; COPDGene Investigators; ECLIPSE Investigators; LifeLines Investigators; SPIROMICS Research Group; International COPD Genetics Network Investigators; UK BiLEVE Investigators; International COPD Genetics Consortium.

Nat Genet. 2017 Mar;49(3):426-432. doi: 10.1038/ng.3752. Epub 2017 Feb 6.

47.

Somatostatin receptor based hybrid imaging in sarcoidosis.

Slart RHJA, Koopmans KP, van Geel PP, Kramer H, Groen HJM, Gan CT, Prakken NHJ, Glaudemans AWJM, Nossent GD.

Eur J Hybrid Imaging. 2017;1(1):7. doi: 10.1186/s41824-017-0014-y. Epub 2017 Dec 15.

48.

Prevalence of HPV Infection in Racial-Ethnic Subgroups of Head and Neck Cancer Patients.

Ragin C, Liu JC, Jones G, Shoyele O, Sowunmi B, Kennett R, Groen HJ, Gibbs D, Blackman E, Esan M, Brandwein MS, Devarajan K, Bussu F, Chernock R, Chien CY, Cohen MA, Samir EM, Mikio S, D'Souza G, Funchain P, Eng C, Gollin SM, Hong A, Jung YS, Krüger M, Lewis J Jr, Morbini P, Landolfo S, Rittà M, Straetmans J, Szarka K, Tachezy R, Worden FP, Nelson D, Gathere S, Taioli E.

Carcinogenesis. 2016 Dec 26. pii: bgw203. doi: 10.1093/carcin/bgw203. [Epub ahead of print]

49.

Structural distress screening and supportive care for patients with lung cancer on systemic therapy: A randomised controlled trial.

Geerse OP, Hoekstra-Weebers JE, Stokroos MH, Burgerhof JG, Groen HJ, Kerstjens HA, Hiltermann TJ.

Eur J Cancer. 2017 Feb;72:37-45. doi: 10.1016/j.ejca.2016.11.006. Epub 2016 Dec 23.

PMID:
28024265
50.

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.

Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF; EMPHASIS-lung Collaborative Group.

J Thorac Oncol. 2017 Apr;12(4):752-762. doi: 10.1016/j.jtho.2016.12.017. Epub 2016 Dec 23.

Supplemental Content

Loading ...
Support Center